iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. The company's proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients. The company was formerly known as Pheton Holdings Ltd and changed its name to iTonic Holdings Ltd. in January 2026. iTonic Holdings Ltd. was founded in 1998 and is headquartered in Beijing, China. iTonic Holdings Ltd. operates as a subsidiary of ZJW (BVI) LTD.…
iTonic Holdings Ltd Regains Compliance with Nasdaq Minimum Bid Price Requirement
iTonic Holdings (NASDAQ: ITOC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 7 employees.
The shares were at 1.590 USD on 20 November 2026, down 82.6% over 52 weeks. Its 52-week range is 1.400 USD to 18.40 USD: the price is 91.4% below the high and 13.6% above the low.
Its market capitalisation is 11.63M USD.
iTonic Holdings reports return on equity of -83.3% and revenue up 49.5% year over year.
It holds more cash than debt, a net cash position of 1.97M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.
No upcoming events tracked.